An error occurred in the article by Boikos et al, titled “Safety of Live-Attenuated Influenza Vaccination in Cystic Fibrosis” published in the October 2014 issue of Pediatrics (2014;134(4):e983–991; doi 10.1542/peds.2014-0887). On page e998, the authors inadvertently counted incorrect numbers of study participants reporting the following adverse events following immunization in Table 3: headache, worsening of cough, increased sputum, abdominal pain, muscle aches, nausea, vomiting, eye redness, difficulty breathing and difficulty swallowing. These miscalculations were due to coding errors and were discovered in the course of conducting a secondary analysis using the same data. The major conclusions of the paper remain unchanged and the sub-analyses pertaining to the adverse events following immunization of wheezing and fever are also the same. Furthermore, these corrections do not change any major conclusions reported in this study. The analyses have been re-run and the corrected version of Table 3 is below. The two largest risk ratios now correspond to difficulty breathing and to redness in both eyes, not joint pain and muscle aches as previously reported. The overall risk of reporting at least one minor symptom during follow up is 2.28 times (95% CI 1.87, 2.78) higher in the first month following live-attenuated influenza vaccination compared with the second month, not 1.43 (95% CI 1.22-1.68) as previously reported.
- Copyright © 2016 by the American Academy of Pediatrics